Designing Olfactory Ensheathing Cell Transplantation Therapies: Influence of Cell Microenvironment

Mariyam Murtaza1,2,3, Lipsa Mohanty1,3, Jenny A. K. Ekberg1,2,3, and James A. St John1,2,3

Abstract
Olfactory ensheathing cell (OEC) transplantation is emerging as a promising treatment option for injuries of the nervous system. OECs can be obtained relatively easily from nasal biopsies, and exhibit several properties such as secretion of trophic factors, and phagocytosis of debris that facilitate neural regeneration and repair. But a major limitation of OEC-based cell therapies is the poor survival of transplanted cells which subsequently limit their therapeutic efficacy. There is an unmet need for approaches that enable the in vitro production of OECs in a state that will optimize their survival and integration after transplantation into the hostile injury site. Here, we present an overview of the strategies to modulate OECs focusing on oxygen levels, stimulating migratory, phagocytic, and secretory properties, and on bioengineering a suitable environment in vitro.

Keywords
OECs, microenvironment, stimulation, cell transplantation, neural repair

Introduction
The olfactory system has a unique neurogenic niche in which olfactory sensory neurons are replaced throughout an individual’s lifespan. Because the olfactory neuroepithelium is exposed to the external environment, there is a constant turnover of olfactory neurons, and newborn olfactory neurons are supported and guided by specialized glia called olfactory ensheathing cells (OECs). OECs are located in the lamina propria underlying the olfactory mucosa and surround the axons of the olfactory sensory neurons from the epithelium up into the nerve fiber layer of the olfactory bulb1–3. Thus, OECs can be easily obtained from an intranasal biopsy of the olfactory mucosa including the lamina propria. OECs share morphological and molecular features with both central nervous system (CNS) glia such as astrocytes, and peripheral glia such as Schwann cells4–6. They support the continual regeneration of neurons by acting as a suitable substrate, and by migrating in tandem or ahead of emerging olfactory axons7–9. OECs are also considered to be the primary innate immunocytes in the olfactory system. They are a dynamic cell population that can be stimulated from a resting state to a phagocytic state, and they are capable of clearing bacteria and axonal debris10,11. Due to their numerous properties, the transplantation of OECs to repair injuries in other regions of the nervous system, particularly spinal cord injury (SCI), is being explored by many research groups.

An injury to the spinal cord is devastating and often an irreversible event that usually triggers multiple deleterious processes such as delayed and progressive cell death, ischemia, hypoxia, inflammation, and extensive scarring12. This complex injury site microenvironment is proapoptotic and anti-regenerative13. To overcome these inhibitory factors, OECs have been trialed extensively for SCI repair because of their versatile and favorable biological functions which can ameliorate the environment of the injury site and promote regeneration. OECs can offer neuroprotection, enhance neurite outgrowth, provide axonal

1 Griffith Institute for Drug Discovery, Griffith University, Brisbane, QLD, Australia
2 Menzies Health Institute Queensland, Griffith University, Southport, QLD, Australia
3 Clem Jones Centre for Neurobiology and Stem Cell Research, Griffith University, Brisbane, QLD, Australia

Submitted: May 30, 2022. Revised: August 8, 2022. Accepted: August 26, 2022.

Corresponding Authors:
Mariyam Murtaza, Griffith Institute for Drug Discovery, Griffith University, Brisbane, QLD 4111, Australia.
Email: m.murtaza@griffith.edu.au

James A. St John, Griffith Institute for Drug Discovery, Griffith University, Brisbane, QLD 4111, Australia.
Email: j.stjohn@griffith.edu.au
guidance cues, and promote remyelination in animal models and in humans (reviewed in Gómez et al.14). Despite several completed clinical trials with transplantation of OECs demonstrating safety and efficacy, the recovery outcomes in patients are often variable. While there are multiple factors contributing to the variable recovery outcomes such as differences in cell source, cell purity, cell delivery techniques, and assessment of functional readouts (reviewed in Kawaja et al.15, Miah et al.16, Yao et al.17), a consistent observation across studies has been the poor survival of transplanted cells, with the reported survival rates of transplanted OECs being as low as 0.3% to 3% in animal models18–21. To compensate for this massive cell loss post-transplantation, excess cells are transplanted into the injury site. However, this approach comes with limitations as it introduces additional cytotoxic products (apoptotic corpses) at the injury site without any improvement in viability. In addition, it is not always feasible to produce a surplus of cells for autologous therapies due to the limitations in cell production from a small biopsy source material. While the majority of our knowledge on OEC biology comes from using rodent olfactory tissues, OECs have also been isolated and purified from different species such as dogs, pigs, primates, and humans22–26. There are fundamental inter-species differences in the control of OEC proliferation and their response to different growth factors (reviewed in Wewetzer et al.27). To overcome the complexities in culturing OECs from different species, it is important to identify and maintain cells under optimal conditions that favor cell proliferation and rapid expansion while maintaining cell-specific properties such as morphology, antigen expression, and phagocytosis. For OECs to be used clinically for cell transplantation, it will be imperative to produce sufficient purified cells in a short timeframe in vitro. Therefore, it is critical to test protocols for cell isolation, purification, and expansion for OECs obtained from individual species to predetermined optimal culture conditions, rather than assume cells from different species will respond similarly.

Strategies need to be designed that enable the in vitro production of OECs in a state that will optimize their survival and integration after transplantation into the hostile injury site. However, commonly used in vitro models for cell expansion do not reflect the conditions of the injury site and this critical aspect of the OEC transplantation therapy is mostly unexplored. By implementing pretreatment strategies for the culture of OECs in an environment mimicking the host site before transplantation, their phagocytic, secretory, and migratory capacity can be improved to enhance viability and neural regeneration at the transplantation site. This review focuses on the following themes prior to cell transplantation of OECs: (1) homeostatic/hypoxic preconditioning and (2) priming/activating cells, and (3) bioengineering a suitable microenvironment.

**Homeostatic/Hypoxic Preconditioning of OECs**

Oxygen availability is a fundamental requirement for cellular function, and decreased oxygen levels can induce cellular stress. Under homeostatic conditions, cells require oxygen levels between 2% and 9% (14.4–64.8 mm Hg), whereas lower oxygen levels 0.5% to 2% (<10 mm Hg) are considered hypoxic28. Standard cell culture practice involves culturing cells in liquid medium incubated at atmospheric oxygen levels of 21% which is considerably higher than physiological oxygen levels. Continued exposure to oxygen concentration above physiological levels can lead to premature senescence of primary cells29,30. It is likely that cells are physiologically adapted to their anatomic niche conditions. By culturing cells ex vivo under higher oxygen levels and then transplanting them in vivo to homeostatic or hypoxic conditions, the cells may require significant re-adaptation which may confer additional cellular stress. This may be a contributing factor to the poor survival of OECs after transplantation. Hence, there is a need for in vitro approaches to mimic the low oxygen conditions that the cells experience in their tissue-specific niche and the transplantation site.

To gain insight into the potential for homeostatic oxygen or hypoxic preconditioning where cells are cultured under low oxygen conditions, it is useful to examine how other cells respond, such as mesenchymal stem cells (MSCs; Table 1). The aims of homeostatic/hypoxic preconditioning are to improve the viability of the cell product and the therapeutic properties of the transplanted cells. Culturing bone marrow–derived mesenchymal stem cells (BM-MSCs) in hypoxic conditions has been shown to increase proliferation, multipotency, and the secretion of cytoprotective molecules49,52. This has partly been attributed to the provision of oxygen levels similar to the resident cellular niche. The cellular niche encompasses the local microenvironment that includes both cellular and acellular components that nourish and regulate the functions of cells. Oxygen levels in the niches of mesenchymal and neural stem cells are 2% to 8% and 1% to 8%, respectively53,54.

Olfactory mucosa–mesenchymal stem cells (OM-MSCs) are a type of Nestin-positive stem cells identified55 in the olfactory mucosa that have the potential to differentiate into smooth muscle cells, adipocytes, osteocytes, and neurons and show similar antigenic profile to BM-MSCs56,57. The OM-MSCs secrete anti-inflammatory cytokines and have been shown to improve myelination of rat spinal cord cell cultures58. Due to these favorable properties, OM-MSCs are an alternative source of MSCs for autologous cell transplantation. OM-MSCs and OECs are resident within the same niche, the highly cellular lamina propria (reviewed in Lindsay et al.59). The application of conditions tested on OM-MSCs to OECs can be an appropriate strategy to recreate an optimized microenvironment for the culture and expansion of OECs, and to improve their efficacy for cell transplantation.
| Cell type             | Hypoxia method       | Oxygen levels and duration | Potential therapeutic application                      | Observations                                                                                                                                                                                                 | References |
|----------------------|----------------------|-----------------------------|--------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|
| Human OM-MSCs        | Not mentioned        | 3% (48 h)                  | Ischemic disease                                       | Hypoxia generated OM-MSCs extracellular vesicles promote paracrine HIF-1α, VEGF signaling for angiogenesis, and enhanced proliferation and migration of human brain microvascular endothelial cells                                | Ge et al.31|
| Human OM-MSC         | 92% N2               | 3% (48 h)                  | Intracerebral hemorrhage                               | Preconditioning of OM-MSC in hypoxia delays senescence and aids in the therapeutic efficacy of OM-MSCs in intracerebral hemorrhage model. microRNA-326 (miR-326) expression was significantly increased in the hypoxia OM-MSCs.       | Liu et al.32|
| Human OM-MSC         | Not mentioned        | Below 0.5% O₂              | Cerebral ischemia/reperfusion injury                   | OM-MSCs attenuated apoptosis and oxidative stress in ischemic stroke models and improved neurologic deficits in rats                                                                                       | He et al.33|
| Human OM-MSC         | 94% N2               | 1% (48 h)                  | Cerebral ischemia/reperfusion injury                   | Hypoxia preconditioned OM-MSCs alleviate pyroptosis and apoptosis of microglial cells by HIF-1α activation of Jβ-tubulin and Tyrosine hydroxylase expression | Huang et al.34|
| Human OM-MSC         | Not mentioned        | 3%                         | Parkinson’s disease                                    | OM-MSCs differentiated into dopaminergic neurons at physiological oxygen level of 3%. Increase in Jβ-tubulin and Tyrosine hydroxylase expression                                                          | Zhuo et al.35|
| Human OM-MSC         | Not mentioned        | 3% (48 h)                  | Cerebral ischemia                                      | Hypoxia reduced gene expression at 5% serum of VEGF, GDNF, BDNF, and NGF and increased expression of Matrix metalloproteinase-2 and BDNF at 20% serum conditions                                           | Yuan et al.36|
| Human BM-MSCs        | Anaerobic chamber    | 2% O₂ (48 or 72 h)         | Spinal cord injury repair                              | In vitro hypoxic pretreatment enhanced cell survival of transplanted BM-MSCs after spinal cord injury                                                                                                     | Luo et al.37|
| Human BM-MSCs and porcine BM-MSCs | HypOxystation | 1%, 2%, or 5% for short term (48 h) and long term (10 days) | Acute respiratory distress syndrome                    | At 2% hypoxia, MSCs exhibited increased proliferation, self-renewal, and modulation of inflammatory genes. Potential to obtain MSCs with augmented function for therapeutic application | Antebi et al.38|
| Human BM-MSC         | Hypoxic C-chamber    | 1% (24 h)                  | BM-MSC stem cell therapy                               | Hypoxia induced HIF-1α enhanced the migration of BM-MSC through activation of matrix metalloproteinase-2                                                                                             | Choi et al.39|
| Human BM-MSCs        | 94% N2               | 5% O₂                      | BM-MSC stem cell therapy                               | Hypoxia increased proliferation and differentiation of BM-MSCs in both young and old healthy donors depending on age and culture conditions                                                              | Mohd et al.40|

(continued)
| Cell type         | Hypoxia method                                                                 | Oxygen levels and duration | Potential therapeutic application                          | Observations                                                                                     | References |
|------------------|-------------------------------------------------------------------------------|----------------------------|----------------------------------------------------------|--------------------------------------------------------------------------------------------------|------------|
| Human BM-MSCs    | 94% N2 Hypoxic C-Chamber connected to ProOx Model 21 controller              | 2% O₂ for 24 h            | Upscaling MSC production for cell therapies             | Hypoxia increased the size and number of neurospheres generated from BM-MSCs                     | Mung et al.41 |
| Human BM-MSCs    |                                                                                           | 1% (48 h)                 | Improving in vitro culture conditions for clinical application | Efficient expansion of BM-MSCs at 2% O₂ compared with 20% O₂. Increased cell proliferation and cellular metabolism | Dos Santos et al.42 |
| Mouse BM-MSCs    | Hypoxic cell incubator                                                         | 1% (48 h)                 | Spinal cord injury repair                                | Hypoxic preconditioning increased exosome production and the exosomes promoted functional recovery following SCI in mice by shuttling miR-216a-5p | Liu et al.43  |
| Mouse BM-MSCs    | ProOx-C-Chamber                                                                 | 1.5% O₂ (48 h)            | Pulmonary fibrosis                                        | Hypoxic preconditioning promoted cell proliferation, expansion, and reduced hydrogen peroxide induced cytotoxicity. Improved survival and lung function in bleomycin-induced pulmonary fibrotic mice was also observed | Lan et al.44 |
| Mouse BM-MSCs    | ProOx C-chamber system                                                         | 0.1%–0.3% O₂ (24 h)       | Ischemic stroke in mice                                  | Intranasally delivered hypoxic preconditioned BM-MSCs showed enhanced homing to ischemic region and improved sensorimotor recovery in treated mice | Wei et al.45 |
| Mouse BM-MSCs    | 94% N2                                                                         | 1%                        | Neovascularization and microvascular network remodeling | Enhanced cell migration and three-dimensional capillary-like structure formation in Matrigel. Increased expression of angiogenesis related markers | Annabi et al.46 |
| Rat BM-MSCs      | 90% N2 Incubator chamber                                                       | 5% O₂                     | Wound healing                                            | Hypoxic pretreatment in combination with curcumin enhanced cell survival, mitochondrial fusion, and accelerated wound healing in a mice wound model | Wang et al.47 |
| Rat BM-MSCs      | 92% N2                                                                         | 3% O₂ (24 h)              | Spinal cord ischemia/reperfusion injury                 | Hypoxic preconditioning improved protective effects of BM-MSCs on neurological function, tissue damage, and inhibited apoptosis | Wang et al.48 |
| Bovine BM-MSCs   | 93% N2 Hypoxystation                                                           | 2% O₂ (1 week)            | Musculoskeletal tissue regeneration                      | Hypoxic preconditioning promoted BM-MSCs survival and extracellular matrix production in low oxygen and nutrient limited in vitro microenvironment | Peck et al.49 |
| Human UC-MSCs    | 94% N2                                                                         | 1% O₂ (72 h)              | Ischemia                                                 | Hypoxic stimulation increased production of microvesicles. These microvesicles promoted new vessel formation | Zhang et al.50 |
| UC-MSCs          | Various levels of N₂ gas was used                                              | 1.5%, 2.5%, and 5% O₂ (72 h) | Stem cell therapy                                       | Hypoxia induced high metabolism rate at 1.5% and 2.5% O₂ in UC-MSCs, reduced cell death, and increased cell proliferation | Lavrentieva et al.51 |

OM-MSC: olfactory mucosa–mesenchymal stem cell; HIF-1α: hypoxia-inducible factor 1-alpha; VEGF: vascular endothelial growth factor; GDNF: glial-derived neurotrophic factor; BDNF: brain-derived neurotrophic factor; NGF: nerve growth factor; BM: bone marrow; SCI: spinal cord injury; UC: umbilical cord.
Similar to BM-MSCs, hypoxic preconditioning of OM-MSCs resulted in increased secretion of neuroprotective paracrine factors against cerebral ischemia/reperfusion injury. Interestingly, hypoxic OM-MSCs were able to inhibit microglial cell death following cerebral ischemia/reperfusion injury in vitro. This anti-pyrototic and anti-apoptotic effect of OM-MSCs on microglia was mediated by regulating expression levels of hypoxia-inducible factor 1-alpha (HIF-1α), a key transcription factor regulating cellular response to hypoxia. Preconditioning of OM-MSCs resulted in marked increase of HIF-1α, and silencing HIF-1α resulted in marked increase of HIF-1α expression levels of hypoxia-inducible factor 1-alpha (HIF-1α) and activation of tyrosine hydroxylase. Thus, it is clear that MSCs respond in various ways to low oxygen conditions and hence the effect of low oxygen conditions should be considered for OECs.

Survival of OECs in culture and at the transplantation site can be compromised by a lack of oxygen and nutrients to support their viability. In vitro sensitivity of OECs to hypoxia and serum deprivation was tested by Pellitteri et al., in neonatal mouse OEC cultures. OEC proliferation and survival were reduced when exposed to a combination of hypoxia and serum starvation. Addition of basic fibroblast growth factor, a mitogen for OECs, could improve survival and proliferation of OECs from hypoxia or serum deprivation. Intriguingly, the growth rate of primate OECs was unaffected by environmental oxygen concentration in contrast to rodent OECs which appeared to overcome replicative senescence when cultured in low oxygen conditions.

A recent study investigated the therapeutic effects of exosomes from human umbilical cord–derived MSCs on OECs in hypoxic conditions for sciatic nerve regeneration in rats. Treating OECs with exosomes resulted in improved viability, proliferation, and migration of OECs, and increased the secretion of brain-derived neurotrophic factor (BDNF) thereby resulting in improved functional recovery in injured rats. Notably, extracellular vesicles derived from hypoxia-preconditioned OM-MSCs (3% O₂) could promote HIF-1α–vascular endothelial growth signaling in human brain microvascular endothelial cells via miR-612 upregulation and downregulation of TP53, a component of cellular stress responses, resulting in enhanced angiogenesis in in vitro tube formation assays.

While these studies make a case for preconditioning cells to low oxygen conditions before transplantation into a “hostile” hypoxic environment, the adoption of low oxygen pretreatment to a clinical setting will be contingent on the protocol consistency. It will be critical to predetermine the vulnerability and responses of the OEC cellular product to hypoxic stress, the duration and percentage O₂ of low oxygen exposure, and ultimately the ideal conditions to improve cell survival and integration at the transplantation site.

### Pretransplantation Cell Priming

The inflammatory environment and the inhibitory extracellular matrix at the injury site in the CNS result in poor growth conditions for both the endogenous and transplanted cells. OECs offer a potential therapeutic benefit as they can modulate the inflammatory environment, remove cell and myelin debris, and offer neurotrophic and physical support to regenerating axons. Many aspects of OECs and their cellular interactions for pro-regenerative functions have been studied in vitro using assays for neurite outgrowth, interaction with astrocytes, debris clearance, and phagocytosis. One avenue to further improve the therapeutic efficacy of OECs is to enhance their activities. Thus, there is a need for the design of approaches to activate or train OECs to attain a functionally relevant phenotype in vitro and to retain or enhance their relevant function in vivo after transplantation.

Different approaches have been tested to stimulate the secretion of growth factors, and to enhance the migratory and phagocytic capabilities of OECs. The main objectives of cell priming or preconditioning cells by exposure to an activating/priming agent in vitro are to augment their potential therapeutic properties and to better prepare the cells to face the conditions at the transplantation site.

### Soluble signaling cues

OECs secrete many neurotrophic molecules such as neurotrophin-3 (NT-3), nerve growth factor (NGF), glial-derived neurotrophic factor (GDNF), BDNF, neurotrophins-4/5 (NT-4/5), and vascular endothelial growth factor (VEGF). These molecules can also counteract the diffusion of inhibitory molecules from neuronal debris by phagocytosing debris.

To optimize the functional outcomes from OEC transplantation, cell modulation with different neurotrophins has been tested (reviewed in Rosner et al. and Wright et al.). NT-3 is an interesting candidate as it can promote both the proliferation and survival of OECs, and different groups have shown that local application of NT-3 at the injury site was favorable for regeneration after SCI. To achieve long-term and site-specific delivery of NT-3 to the injury site, OECs genetically modified to secrete high amounts of NT-3 were transplanted to the injured spinal cord, and these cells could significantly improve axonal outgrowth. A recent study explored the effect of NT-3 in a rat model of SCI and showed that NT-3 could inhibit the mitogen-activated protein kinase (MAPK) signaling pathway. Similarly, NGF and BDNF play a neuroprotective role by modulating the MAPK/mitogen-activated extracellular signal-related kinase (MEK) pathway.

The Wingless-related integration site (Wnt) signaling pathway influences multiple aspects of neural development from cell proliferation, cell fate specification, and neuronal morphogenesis to cell death (reviewed in Ciani and Salinas).
A specialized subgroup of OECs in the inner nerve layer of the olfactory bulb was identified using Wnt reporter mice, and Wnt signaling was implicated in appropriate olfactory axonal targeting and in neural regeneration. Notably, the activation of Wnt signaling could promote self-renewal of olfactory epithelial stem cells and neuronal differentiation. Furthermore, Wnt signaling activation is critical for the regeneration of adult olfactory epithelium after methimazole induced injury. Activation of canonical Wnt signaling was shown to be both necessary and sufficient to drive the transition of horizontal basal stem cells from a resting to an activated neurogenic state in the uninjured epithelium. Recently, it was reported that Wnt-activated OECs can stimulate neural stem cell proliferation and neuronal differentiation in neonatal mouse OECs. Interestingly, the conditioned medium from Wnt-activated OECs was sufficient to stimulate proliferation of neural stem cells determined by an increase in Ki67 and Sox2 double positive cells, and it could also promote the differentiation of neural stem cells into β-tubulin III positive neurons.

There is growing evidence supporting a paracrine/secretory effect of transplanted cells such as MSCs and OECs on neural regeneration (reviewed in Makridakis et al.). These studies indicate that there may not be a need for homing of large cell numbers to the injury site to observe an effect. Secreted signaling cues could be sufficient to drive cellular responses, and there is potential for using activation or stimulation of the cells as another approach to enhance

Figure 1. Schematic of the various biological roles of olfactory ensheathing cells that favour neural regeneration. The therapeutic effects of olfactory ensheathing cell transplantation for neural repair are attributed to their biological roles such as phagocytosis of debris, interaction with astrocytes, neurotrophic support, immunomodulation, and neuronal regeneration.
therapeutic potency of transplanted cells by improving their function and their resistance to inflammatory conditions. Little is known about the immunomodulatory properties of OM-MSCs. To address this, Jafari et al., compared the cytokine secretion of stimulated OM-MSCs and adipose-derived MSCs by short-term priming protocols to stimulate Toll-like receptors. Interestingly, OM-MSCs had significantly higher levels of immunosuppressive cytokines interleukin-8, transforming growth factor beta (TGF-β) and C-C motif chemokine ligand 5 secretion in comparison with adipose tissue–derived MSCs even before any treatment. We recently reported that OECs produced less pro-inflammatory cytokines compared with Schwann cells and macrophages when exposed to necrotic bodies and in a pro-inflammatory microenvironment. The secretome of OM-MSCs has been reported previously and the results showed that the secreted proteins were mainly associated with neurotrophy, cell proliferation, migration and integration at the injury site, and has been reported to promote migration and proliferation of OECs via extracellular signal-regulated kinase (ERK1/2) signaling while also facilitating the homing of OECs to the injury site. We recently showed that iraglutide, a glucagon-like peptide-1 receptor agonist, could stimulate OEC migration by reducing time in arrest, upregulating laminin-1, and activating the ERK pathway. Another approach to augment OEC migration at the site of injury is to genetically modify cells. One such study was to modify OECs to express Nogo receptor ectodomain. These modified cells migrated longer than non-modified cells both in vitro and post-transplantation in a rat model of SCI. The myelin mediated inhibition of OEC migration could be partly overcome by treatment with NEP1-40 peptide or antibodies against Nogo receptor. These studies further support the notion that stimulating migration of OECs is feasible, and perhaps incorporating cells with enhanced migratory properties should be a consideration when designing OEC-based cell therapies for neural repair.

Migration. Transplanted cells will encounter a complex and unfavorable environment during their migration as they are faced with different cell types such as reactive astrocytes, activated microglia, invading fibroblasts, inflammatory molecules, and debris at the injury site. These interactions have the potential to modulate the transplanted cells and affect their ability to migrate. It is likely that OECs transplanted at the site of SCI will be surrounded by glial-fibrillary acidic protein-positive cells, possibly reactive astrocytes, and these astrocytes can limit OEC migration. For instance, tumor necrosis factor alpha (TNFα) is secreted by reactive astrocytes at the site of injury and can modulate OEC migration in a dose-dependent fashion, blocking tumor necrosis factor receptor 1 alpha (TNFR1α). This can result in the reduced migration of olfactory bulb OECs. Despite the odds being stacked against migration and integration at the injury site, OECs have been shown to migrate with the regenerating axons and interact with astrocytes. These migratory properties of OECs, along with their ability to interact with astrocytes at the injury site and modulation of the inflammatory environment, are thought to contribute toward favorable neural repair in the CNS. Moreover, OECs can also downregulate the translocation of nuclear factor kappa beta (NFκB) in astrocytes, an important response implicated in astrocyte activation. Insulin-like growth factor-1, secreted by OECs is considered a key contributor to the modulation of astrocytes activation by OECs by potentially preventing the translocation of NFκB to astrocyte nuclei.

Different candidates have been tested to stimulate OEC migration with the objective of improving neural repair outcomes. We have shown previously that OEC migration is characterized by lamellipodial waves that appear to direct intercellular interactions. The lamellipodia migration of OECs could also be enhanced by GDNF which further mediates the motility of axons. Integrin alpha-7 has been reported to play an important role in the migration of adult OECs without directly affecting neurite regeneration. Fibulin-3, Slit2, and NogoA have been shown to inhibit OEC migration, and interestingly they are also often found to be overexpressed in the scar tissue at lesion sites. Similarly, lysophosphatic acid (LPA) is produced at the injury site, and has been reported to promote migration and proliferation of OECs via extracellular signal-regulated kinase (ERK1/2) signaling while also facilitating the homing of OECs to the injury site. We recently showed that iraglutide, a glucagon-like peptide-1 receptor agonist, could stimulate OEC migration by reducing time in arrest, upregulating laminin-1, and activating the ERK pathway. Another approach to augment OEC migration at the site of injury is to genetically modify cells. One such study was to modify OECs to express Nogo receptor ectodomain. These modified cells migrated longer than non-modified cells both in vitro and post-transplantation in a rat model of SCI. The myelin mediated inhibition of OEC migration could be partly overcome by treatment with NEP1-40 peptide or antibodies against Nogo receptor. These studies further support the notion that stimulating migration of OECs is feasible, and perhaps incorporating cells with enhanced migratory properties should be a consideration when designing OEC-based cell therapies for neural repair.

Phagocytosis. The persistence of cellular and myelin debris at the site of CNS injury impedes neural regeneration. Effective stimulation of OEC phagocytic activity is another avenue to promote debris clearance and thereby improve neural regeneration. Accumulating evidence from our group and other studies has helped identify different compounds that can increase OEC phagocytosis, including curcumin, curcumin with lipopolysaccharide (LPS), natural products 2-methoxy-1,4-naphthoquinone, the serratulane diterpenoids 3-acetoxyl-7,8-dihydroxyserrulat-14-en-19-oic acid, and 3,7,8-trihydroxyserrulat-14-en-19-oic acid. The anti-inflammatory cytokine TGF-β has also been implicated in increasing OEC phagocytosis.

Curcumin elicits pleiotropic effects in OECs in a dose-dependent manner. In assays where neurons are co-cultured
with OECs and neuronal debris, increased clearance of debris was observed in the presence of LPS and curcumin stimul-

us or TGF-β, and this in turn promoted neuronal sur-

vival. Strikingly, pretreatment with curcumin resulted in improved functional recovery and axon growth in a rat model of SCI. Cells stimulated by curcumin exhibited increased expression of phosphatidylserine receptor suggestive of increased phagocytosis and secreted more growth factors in vivo at the injury site. Recently, it was shown that when activated by curcumin and LPS, OECs had pro-angiogenic effects such as promoting proliferation, migration, and ves-

sel formation of vascular endothelial cells likely by modulating the phosphatidylinositol 3-kinase/protein kinase B pathway.

Compared with Schwann cells, OECs appear to have more favorable neural repair characteristics. In addition to producing less pro-inflammatory cytokines compared with Schwann cells in a pro-inflammatory environment, we have also demonstrated that OECs phagocytosed more myelin debris than Schwann cells. More data are clearly needed to understand how OECs interact with the immune and nervous systems, and how debris clearance is coordinated between OECs and professional phagocytic cells at the injury site.

Overall, these studies show that OECs are responsive to stimulation and the potential exists that these various activi-

ties can be manipulated to further enhance the therapeutic benefits of OECs after transplantation. To create a microen-

vironment suitable to drive axonal regeneration, we need to develop and test approaches to activate and train OECs in vitro to maximize their functions in vivo. Systematic analysis of the priming agents and optimizing the duration of priming to modulate therapeutic efficacy will be the key to achieving efficient cell therapy outcomes with minimum cell dosage and side effects.

Bioengineering a Suitable Microenvironment

Another challenge in the application of cell therapies for SCIs is the retention of biological functions of transplanted cells. For cells to function consistently as “living drugs,” we must aim to recreate or mimic their in vivo niche in a dish and to standardize cell production protocols. The factors that directly or indirectly affect the cell behavior such as extracellular matrix, neighboring cells, signaling cues, and mechanical forces caused by movement of physiological fluids, all constitute the microenvironment of a cell.

OECs are conventionally cultured in vitro and expanded as adherent monolayers under conditions commonly used for mammalian cells. However, access to nutrition and oxygen is not uniform and well-controlled under these conditions, and intercellular interaction is unnatural when cells are adhered to a dish. Moreover, the properties of these cells are dependent on factors such as cell density and time in culture. Cells are also reliant on direct contact with the surrounding extra-

cellular matrix and neighboring cells for maintenance and regulation of their biological function. So, two-dimensional adherent culture conditions are not ideal, and there is a disparity between what the cells require for performing their biological roles and what is provided in vitro. There is a need for developing models mimicking both the resident cellular niches and the transplantation niche.

Rapid advances in materials science have led to the use of different biomaterials with the aim of promoting functional tissue repair at the site of injury. Provision of three-

dimensional (3D) support has been shown to improve efficacy of BM-MSCs after transplantation by mimicking the cellular niche, and creating a conducive and stable environment for axonal regeneration and cell survival (reviewed in Zhou et al.).

Different biomaterials have been trialed in combination with OECs with varying success (Table 2). These biomateri-

als function as carriers for the cells and as structural scaffolds for axonal regrowth. The minimum prerequisites for a suit-

able biomaterial are biocompatibility, biodegradability, and adaptive mechanical properties. Despite the application of fabricated and synthetic 3D scaffolds such as fibrin and poly-

mer-based scaffolds for nerve repair, there remains a need for biologically relevant scaffolds or scaffold-free 3D culture techniques. It is expected that decellularized scaffold-based tissue constructs could be directly transplanted for the regrowth of axonal tracts and to hasten the neural regeneration in vivo. Decellularization is the process of creating an acellular extracellular matrix scaffold by removal of the cellular components of living tissues. These acellular scaffolds are subsequently used to provide structural and spatial sup-

port, cytokine support, and integration through cell surface molecules. Spinal cord decellularized scaffolds have been shown to promote axonal regeneration and functional motor recovery in the hind limbs of rats with SCI. Decellularized scaffolds seeded with OECs showed good biocompatibility with adherent and proliferating OECs observed in the scaffold, and when transplanted into rat spinal cord, the decellularized scaffold + OEC group could promote axonal regeneration and showed significant motor function recovery after 3 weeks of injury. However, decel-

lularized materials which have a fixed architecture restrict to some degree the movement and interactions of cells that are seeded into the 3D construct. Thus, the resultant cell relationships may not reflect a more natural arrangement that may occur if the cells had a less restrictive environment.

To simplify the final cell product that is transplanted and to minimize potential adverse effects, our research has focused on the development of stable 3D constructs that are substrate and scaffold-free and can be cultured in standard cell culture medium. We recently reported two 3D spheroid culture systems: floating liquid marbles and the naked liquid marbles. In the naked liquid marble system, OECs were cultured within a liquid drop on a superhydrophobic surface can form spheroids within hours. This rapid formation of spheroids is advantageous as short-term cultured OECs have...
| Study                                                                 | Cell types                  | Scaffold type                      | Outcome                                                                                                                                                                                                 | References       |
|----------------------------------------------------------------------|-----------------------------|-----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|
| Partial recovery with dorsal root injury in rats                     | Human olfactory bulb OECs   | 3D collagen scaffold              | 4.8 mg/ml collagen with $1 \times 10^6$ cells gave an optimal cellular network of OECs. Microglial activation in the deep dorsal horn of cervical C7 and C8 level or axonal loss in C3 level was observed in the responder rats; 30% errors observed in climbing performance of control rats compared with rats with OEC transplants | Collins et al.122|
| Injury model: Rat unilateral four root dorsal transection injury      |                             |                                   | Implantation of collagen scaffold seeded with OECs did not improve or worsen motor outcomes and allodynia following thoracic SCI hemisection in rats                                                                 | Deumens et al.123|
| (C6, C7, C8, and T1 region)                                          |                             |                                   |                                                                                                                                                                                                       |                  |
| OEC collagen grafts do not improve spinal trauma-induced motor deficits. | Rat olfactory bulb OECs     | 2 mm long cylindrical collagen scaffolds with diameter of 2 mm | 3D collagen scaffold is biocompatible with OECs and scaffolds yielded 67% more OECs compared with monolayer culture. Also, spindle-like bipolar morphology of OEC was retained on 3D collagen scaffolds | Wang et al.124   |
| Injury model: Rat 2 mm long unilateral low—thoracic hemisection cavities (T13 region) |                             |                                   |                                                                                                                                                                                                       |                  |
| Phenotypic study of rat OECs on 3D collagen scaffolds                 | Rat olfactory bulb—derived OECs | The average pore size of the 3D collagen scaffold was 20–100 \( \mu \text{m} \) in diameter | Water-rinsed silk fibroin scaffolds were biocompatible with OECs, favored cell proliferation and secretion of neurotrophic factors                                                                 | Wang et al.125   |
| In vitro biocompatibility of OECs with biomimetic silk scaffold       | Rat olfactory bulb OECs      | Bombyx mori porous silk scaffold  |                                                                                                                                                                                                       |                  |
| Optimal diameter of scaffold helps in guiding growth and migration of OECs | Rat olfactory bulb OECs     | SFS                               | 300 nM SFS is biocompatible for culture and unidirectional migration of OECs                                                                                                                                 | Shen et al.126    |
| Microencapsulation of transplanted OECs reduce pain post sciatic nerve injury | Rat olfactory bulb OECs     | Cell suspension was mixed 1:1 with 1.5% alginic acid | Purinergic receptor P2X2/3 expression is elevated in chronic constriction injury (CCI) models.                                                                                                         | Zhao et al.127    |
| L4–L5 dorsal root ganglia C chronic sciatic nerve compression injury  | Rat olfactory bulb OECs     | 2% alginate, alginate-0.025% fibronectin hydrogel 500–800 \( \mu \text{m} \) alginate and matrigel preparation | Alginate-fibronectin increased proliferation of OECs but significantly lower than with matrigel. Neurite outgrowth of OECs was increased in alginate-fibronectin hydrogel compared with alginate alone | Novikova et al.128|
| Potential biomaterials functioning as cell carriers for neuro transplantation | Rat olfactory bulb OECs     | Single-walled carbon nanotube/poly (L-lactic acid) (SWCNT/PLLA) scaffolds | OEC-seeded nerve conduits transplanted to the transected rat sciatic nerve improved axonal growth and peripheral nerve regeneration                                                                                                                                 | Kabiri et al.129  |
| Neuroregenerative properties of OECs in multilayered conductive nanofibrous conduits | Rat olfactory bulb OECs     | Poly(\( \alpha, \beta \))-lactide matrices | Lack of OEC/ONF migration from the rostral/caudal site of injection to injury site and poor cell survival on biomatrices due to low seeding numbers of OEC/ONF and incompatibility of biomatrices. Modest locomotory function seen in swing speed, stride length in hind limbs, and axonal regrowth after OEC/ONF transplantation | Deumens et al.130 |
| Injury model: 8 mm transected sciatic nerve in rats                   |                             |                                   |                                                                                                                                                                                                       |                  |
| Long-distance axon regrowth in presence of OECs, olfactory nerve fibroblasts and biomaterials | Rat olfactory bulb OECs/ONF |                                   |                                                                                                                                                                                                       |                  |
| Injury model: Rat 2 mm long dorsal hemisectioned (T11/T12 region) SCI model |                             |                                   |                                                                                                                                                                                                       |                  |
| Enhanced neural regeneration with OECs in PLGA scaffolds             | Rat olfactory bulb OECs     | PLGA pore size 300–500 µM          | Enhanced locomotor function, axon myelination, neuronal protection, and decreased astrogliosis post SCI in PLGA and OEC combination compared with PLGA or untreated groups                                                                 | Wang et al.131    |
| Injury model: Rat 2 mm wide complete transected (T9–T10 region) SCI model |                             |                                   |                                                                                                                                                                                                       |                  |

(continued)
| Study                                                                 | Cell types                  | Scaffold type                  | Outcome                                                                                                                                                                                                 | References |
|----------------------------------------------------------------------|-----------------------------|-------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|
| Directionality and bipolarity of OECs on electrospun nanofibers     | Rat OECs                    | PLGA                          | Nano composite electrospinning fibers of 237 nm diameter favored bipolarity and unidirectional migration of OECs                                                                                       | Kueh et al. |
| PLGA with OECs for bridging sciatic nerve defects in rats Injury model: 7 mm sciatic was resected to 10 mm nerve defect | Rat olfactory bulb OECs    | 100 µM diameter PLGA (with 85:15 carboxyl end) | A combination of PLGA and OECs can improve the functional and structural outcome in defective sciatic nerve but the sciatic functional index cannot be recovered in more serious injuries | Li et al.  |
| OECs combined with chitosan decreased neuropathic pain Injury model: Chronic sciatic nerve compression injury in rats | Rat olfactory bulb OECs    | Chitosan                      | OEC-seeded chitosan scaffolds can inhibit Purinergic receptor (P2X7R) overexpression and reduce neuropathic pain                                                                                       | Zhang et al. |
| Electrical stimulation of OECs using conductive polymers            | Rat olfactory bulb OECs    | 0.4 mm Polypyrrole/ chitosan polymers | Polypyrrole/chitosan membranes supported cell adhesion and proliferation even without electrical stimulation. Stimulation increased secretion of neurotrophic factors | Qi et al.  |
| 3D printed polycaprolactone/polypyrrole conducting scaffolds aid neurite outgrowth | Human OE-MSCs               | PCL/polypyrrole (PPy) conducting scaffolds | OE-MSCs on scaffolds showed increased differentiation to Schwann-like cells, increased secretion of NGF and BDNF, and increased neurite outgrowth but conductivity of scaffold had no effect on cell attachment, proliferation, viability, and distribution | Entezari et al. |
| Interactions between Schwann cells (SCs) and OECs with starch/polycaprolactone scaffold | Rat olfactory bulb OECs    | SPCL                          | OECs and SCs are biocompatible with SPCL. Improved growth, proliferation, and migration of cells was observed in long-term culture                                                                              | Silva et al. |
| Comparison of scaffolds for migration and growth of glial cells Characterization of OECs cultured on polyurethane/poly lactide scaffold | Rat OECs                    | PCL and C/PCL                 | C/PCL biomaterial made scaffold is better suited for cell proliferation, migration, and neurite outgrowth                                                                                             | Schnell et al. |
| Characterization of OECs cultured on polyurethane/poly lactide scaffold | Rat olfactory bulb OECs    | PU/PLDL scaffold              | Different ratio of PU to PLDL did not alter phenotype of OECs but proliferation rate depended upon equal ratio of polymers                                                                                | Grzesiak et al. |
| BioPEGylation of PHB-polyethylene glycol (PHB-b-DEG) hybrid polymers promotes healthy nerve cell and migration | OECs                        | Polyhydroxybutyrate-polyethylene glycol | bioPEGylated PHB supported OEC migration, promoted cell proliferation and attachment. No cytotoxicity response in OECs                                                                               | Chan et al. |
| Compatibility of OECs with a self-assembling peptide scaffold Albumin scaffold seeded with adipose-derived stem cells and OECs for spinal cord injury repair | Rat olfactory bulb OECs    | A new peptide hydrogel scaffold GRGDSPmx | On the new scaffold, OEC proliferation was increased, cells showed less apoptosis and maintained spindle-shaped morphology                                                                              | Zhang et al. |
| Improved locomotor behavior in rats after delayed cell transplantation into transected spinal cord Injury model: Rat rostrocaudally 3–4 mm complete transected (T9–T11 region) SCI model | Adipose-derived stem cells and rat OECs | Serum-derived albumin scaffold | Rats treated with cell-seeded scaffolds showed improved locomotor skills and presence of cells expressing neuronal markers at injury site                                                                      | Ferrero-Gutierrez et al. |
| Albumin scaffold seeded with adipose-derived stem cells and OECs for spinal cord injury repair                     | Rat olfactory lamina propria | Three to five 1 mm² lamina propria pieces/ Gelfoam | Olfactory lamina propria grafts result in gradual improvement in locomotor recovery and axonal regeneration                                                                                       | Lu et al.  |

OEC: olfactory ensheathing cell; SFS: silk fibroin scaffolds; SCI: spinal cord injury; ONF: olfactory nerve fibroblasts; PLGA: poly (lactic-co-glycolic-acid); OE-MSC: olfactory ecto-mesenchymal stem cell; PCL: poly-ε-caprolactone; NGF: nerve growth factor; BDNF: brain-derived neurotrophic factor; SPCL: starch-based polycaprolactone scaffold; C/PCL: collagen/Poly-ε-caprolactone; PU/PLDL: polyurethane/poly lactide; PHB: polyhydroxybutyrate.
better effects on the neural survival and axonal growth\textsuperscript{152}. Furthermore, we could customize the size of the spheroid using vibration at different frequencies\textsuperscript{153} or by changing cell density.

A major advantage of culturing cells in 3D spheres is that it closely mimics the \textit{in vivo} environment and can recapitulate the cellular interactions and cell-matrix interactions. Importantly, our ability to culture OECs in 3D in this naked liquid marble system revealed two critical attributes of this process: (1) unrestricted movement of cells within liquid marbles enabled natural arrangement of cells reminiscent of their \textit{in vivo} organization and (2) cells retained their migration properties from spheroids when transferred to a two-dimensional culture plate. Due to the naked liquid marble system resulting in 3D cell constructs that closely mimic the \textit{in vivo} environment, it is suitable for a range of \textit{in vitro} studies of OECs which may better reflect cell function and responses.

3D bioprinting is a bespoke approach to address the variable nature of SCIs wherein personalized tissue scaffolds suitable to match an individual’s injury site can be generated. For instance, Joung et al.\textsuperscript{154} reported a 3D spinal cord tissue-like platform where multiple neural progenitor cells could be placed within a printed scaffold. More recently, a novel bioink containing hydroxypropyl chitosan, thiolated hyaluronic acid, vinyl sulfonated hyaluronic acid, and matrigel was used for the fabrication of a tissue scaffold to mimic the white matter of spinal cord\textsuperscript{155}. The feasibility of printing primary cultured OECs was demonstrated by Othon et al.\textsuperscript{156}, where using biological laser printing several lines of OECs could be printed through a multilayer hydrogel scaffold.

In summary, integration of emerging technologies such as 3D bioprinting in combination with scaffold-free models has the potential to create highly complex environments for the recreation of cellular and transplantation niches thereby facilitating the use of predictive and biologically relevant \textit{in vitro} models.

**Conclusion**

The microenvironment of the injured spinal cord is unfavorable for the survival of transplanted cells. In this review, we have discussed potential strategies to precondition and stimulate OECs for transplantation to improve their survival and to enhance their therapeutic potential (Fig. 2). When cells are isolated from their native environment, expanded \textit{in vitro}, and then transplanted back \textit{in vivo} to a harsh injury environment, the therapeutic potency of the cells is not well-preserved, possibly due to changes in the microenvironment of the cells. Preconditioning OECs \textit{in vitro} may improve their migration, phagocytic, and immunomodulatory abilities. Understanding how the manipulation of different stimuli, such as oxygen levels, signaling cues, and 3D culture parameters of cells, can affect the behavior of OECs should be a consideration in the design of cell transplantation therapies. Future studies should focus on the development of robust \textit{in vitro} models that can activate and retain biological properties of the cells by mimicking conditions of the tissue-specific microenvironment. This will help to improve the overall reliability of cell-based therapies and to unlock the therapeutic capabilities of OECs for neural repair.

**Acknowledgments**

We thank Yasmin Arena-Foster for proof-reading the manuscript.

**Ethical Approval**

This study was approved by our institutional review board.
Statement of Human and Animal Rights
This article does not contain any studies with human or animal subjects.

Statement of Informed Consent
There are no human subjects in this article and informed consent is not applicable.

Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by a Clem Jones Foundation grant to JASJ and IAKE; a Motor Accident Insurance Commission of Queensland grant to JASJ, IAKE, and MM; a National Health and Medical Research Council Grant to JASJ and IAKE (APP1183799); and a Perry Cross Foundation Grant to JAKE and JASJ.

ORCID iDs
Mariyam Murtaza  https://orcid.org/0000-0001-7087-3809
Jenny A. K. Ekberg  https://orcid.org/0000-0001-5151-4966
James A. St John  https://orcid.org/0000-0001-7536-3381

References
1. Graziadei GA, Graziadei PP. Neurogenesis and neuron regeneration in the olfactory system of mammals. II. Degeneration and reconstitution of the olfactory sensory neurons after axotomy. J Neurocytol. 1979;8(2):197–213.
2. Graziadei PP, Graziadei GA. Neurogenesis and neuron regeneration in the olfactory system of mammals. I. Morphological aspects of differentiation and structural organization of the olfactory sensory neurons. J Neurocytol. 1979;8(1):1–18.
3. Chuah MI, West AK. Cellular and molecular biology of ensheathing cells. Microsc Res Tech. 2002;58(3):216–27.
4. Beiersdorfer A, Wolburg H, Grawe J, Scheller A, Kirchhoff F, Lohr C. Sublamina-specific organization of the blood brain barrier in the mouse olfactory nerve layer. Glia. 2020;68(3):631–45.
5. Lakatos A, Franklin RJ, Barnett SC. Olfactory ensheathing cells and Schwann cells differ in their in vitro interactions with astrocytes. Glia. 2000;32(3):214–25.
6. Nazareth L, Chen M, Shelper T, Shah M, Tello Velasquez J, Walkden H, Beacham I, Batzloff M, Rayfield A, Todorovic M, Beagley K, et al. Novel insights into the glia limits of the olfactory nervous system. J Comp Neurol. 2019;527(7):1228–44.
7. Doucette R. Glial influences on axonal growth in the primary olfactory system. Glia. 1990;3(6):433–49.
8. Ekberg JA, Amaya D, Mackay-Sim A, St John JA. The migration of olfactory ensheathing cells during development and regeneration. Neurosignals. 2012;20(3):147–58.
9. Tennent R, Chuah MI. Ultrastructural study of ensheathing cells in early development of olfactory axons. Brain Res Dev Brain Res. 1996;95(1):135–39.
10. Nazareth L, Tello Velasquez J, Lineburg KE, Chehrehasa F, St John JA, Ekberg JA. Differing phagocytic capacities of accessory and main olfactory ensheathing cells and the implication for olfactory glia transplantation therapies. Mol Cell Neurosci. 2015;65:92–101.
11. Su Z, Chen J, Qiu Y, Yuan Y, Zhu F, Zhu Y, Liu X, Pu Y. He C. Olfactory ensheathing cells: the primary innate immunocytes in the olfactory pathway to engulf apoptotic olfactory nerve debris. Glia. 2013;61(4):490–503.
12. Rossignol S, Schwab M, Schwartz M, Fehlings MG. Spinal cord injury: time to move? J Neurosci. 2007;27(44):11782–92.
13. Liu XZ, Xu XM, Hu R, Du C, Zhang SX, McDonald JW, Dong HX, Wu YJ, Fan GS, Jacquin MF, Hsu C, et al. Neuronal and glial apoptosis after traumatic spinal cord injury. J Neurosci. 1997;17(14):5395–406.
14. Gómez RM, Sánchez MY, Portela-Lomba M, Ghotme K, Barreto GE, Sierra J, Moreno-Flores MT. Cell therapy for spinal cord injury with olfactory ensheathing glia cells (OECs). Glia. 2018;66(7):1267–301.
15. Kawaja MD, Boyd JG, Smithson LJ, Jahed A, Doucette R. Technical strategies to isolate olfactory ensheathing cells for intraspinal implantation. J Neurotrauma. 2009;26(2):155–77.
16. Miah M, Ferretti P, Choi D. Considering the cellular composition of olfactory ensheathing cell transplants for spinal cord injury repair: a review of the literature. Front Cell Neurosci. 2021;15:781489.
17. Yao R, Murtaza M, Velasquez JT, Todorovic M, Rayfield A, Ekberg J, Barton M, St John J. Olfactory ensheathing cells for spinal cord injury: sniffing out the issues. Cell Transplant. 2018;27(6):879–89.
18. Barakat DJ, Gagliani SM, Neravetla SR, Sanchez AR, Andrade CM, Pressman Y, Puzis R, Garg MS, Bunge MB, Pearse DD. Survival, integration, and axon growth support of glia transplanted into the chronically contused spinal cord. Cell Transplant. 2005;14(4):225–40.
19. Pearse DD, Sanchez AR, Pereira FC, Andrade CM, Puzis R, Pressman Y, Golden K, Kitay BM, Blits B, Wood PM, Bunge MB. Transplantation of Schwann cells and/or olfactory ensheathing glia into the contused spinal cord: survival, migration, axon association, and functional recovery. Glia. 2007;55(9):976–1000.
20. Roshamwala R, Shah M, St John J, Ekberg J. Survival and integration of transplanted olfactory ensheathing cells are crucial for spinal cord injury repair: insights from the last 10 years of animal model studies. Cell Transplant. 2019;28(Suppl 1):132S–159S.
21. Roet KC, Eggers R, Verhaagen J. Noninvasive bioluminescence imaging of olfactory ensheathing glia and Schwann cells following transplantation into the lesioned rat spinal cord. Cell Transplant. 2012;21(9):1853–65.
22. Carwardine D, Prager J, Neeves J, Muir EM, Unej Y, Granger N, Wong LF. Transplantation of canine olfactory ensheathing cells producing chondroitinase ABC promotes chondroitin sulphate proteoglycan digestion and axonal sprouting following spinal cord injury. PLoS ONE. 2017;12(12):e0188967.
23. Techangamsuwan S, Imbschweiler I, Kreutzer R, Kreutzer M, Baumgartner W, Wewetzer K. Similar behaviour and primate-like properties of adult canine Schwann cells and olfactory ensheathing cells in long-term culture. Brain Res. 2008;1240:31–38.

24. Imaizumi T, Lankford KL, Burton WV, Fodor WL, Kocsis JD. Xenotransplantation of transgenic pig olfactory ensheathing cells promotes axonal regeneration in rat spinal cord. Nat Biotechnol. 2000;18(9):949–53.

25. Rubio MP, Muñoz-Quiles C, Ramón-Cueto A. Adult olfactory bulbs from primates provide reliable ensheathing glia for cell therapy. Glia. 2008;56(5):539–51.

26. Feron F, Perry C, Cochrane J, Licina P, Nowitzke A, Urquhart S, Geraghty T, Mackay-Sim A. Autologous olfactory ensheathing cell transplantation in human spinal cord injury. Brain. 2005;128(Pt 12):2951–60.

27. Wewetzer K, Radtke C, Kocsis J, Baumgärtner W. Species-specific control of cellular proliferation and the impact of large animal models for the use of olfactory ensheathing cells and Schwann cells in spinal cord repair. Exp Neurol. 2011;229(1):80–87.

28. Simon MC, Keith B. The role of oxygen availability in embryonic development and stem cell function. Nat Rev Mol Cell Biol. 2008;9(4):285–96.

29. Pannierello S, Samper E, Krtolica A, Goldstein J, Melov S, Murtaza et al. Embryonic development and stem cell function. Nat Rev Mol Cell Biol. 2003;5(8):741–47.

30. Sherr CJ, DePinho RA. Cellular senescence: mitotic clock or culture shock? Cell. 2000;102(4):407–10.

31. Ge L, Xun C, Li W, Jin S, Liu Z, Zhuo Y, Duan D, Hu Z, Chen P, Lu M. Extracellular vesicles derived from hypoxia-preconditioned olfactory mucosa mesenchymal stem cells enhance angiogenesis via miR-612. J Nanobiotechnology. 2021;19(1):380.

32. Liu J, He J, Ge L, Xiao H, Huang Y, Zeng L, Jiang Z, Lu M, Hu Z. Hypoxic preconditioning rejuvenates mesenchymal stem cells and enhances neuroprotection following intracerebral hemorrhage via the miR-326-mediated autophagy. Stem Cell Res Ther. 2021;12(1):413.

33. He J, Liu J, Huang Y, Zhuo Y, Chen W, Duan D, Tang X, Lu M, Hu Z. Olfactory mucosa mesenchymal stem cells alleviate cerebral ischemia/reperfusion injury via Golgi apparatus secretory pathway Ca(2+)-ATPase isomorform 1. Front Cell Dev Biol. 2020;8:586541.

34. Huang Y, Tan F, Zhuo Y, Liu J, He J, Duan D, Lu M, Hu Z. Hypoxia-preconditioned olfactory mucosa mesenchymal stem cells abolish cerebral ischemia/reperfusion-induced pyroptosis and apoptotic death of microglial cells by activating HIF-1alpha. Aging (Albany NY). 2020;12(11):10931–50.

35. Zhuo Y, Wang L, Ge L, Li X, Duan D, Teng X, Jiang M, Liu K, Yuan T, Wu P, Wang H, et al. Hypoxic culture promotes dopaminergic-neuronal differentiation of nasal olfactory mucosa mesenchymal stem cells via upregulation of hypoxia-inducible factor-1alpha. Cell Transplant. 2017;26(8):1452–61.

36. Yuan T, Zhuo Y, Su C, Li X, Duan D, Ge L, Wu P, Wang H, Deng Y, Lu M. Hypoxic and ischemic effects on gene and protein expression levels of paracrine factors by human olfactory mucosa mesenchymal-like stem cells. J Neurorestoratol. 2016;4:85–94.

37. Luo Z, Wu F, Xue E, Huang L, Yan P, Pan X, Zhou Y. Hypoxia preconditioning promotes bone marrow mesenchymal stem cells survival by inducing HIF-1a in injured neuronal cells derived exosomes culture system. Cell Death Dis. 2019;10(2):134.

38. Antebi B, Rodriguez LA, Walker KP, Asher AM, Kamucheka RM, Alvarado L, Mohammadi A, Cancio LC. Short-term physiological hypoxia potentiates the therapeutic function of mesenchymal stem cells. Stem Cell Res Ther. 2018;9(1):265.

39. Choi JJ, Lee YB, Jung J, Hwang SG, Oh IH, Kim GJ. Hypoxia inducible factor-1α regulates the migration of bone marrow mesenchymal stem cells via integrin α4. Stem Cells Int. 2016;2016:7932185.

40. Mohd Ali N, Boo L, Yeap SK, Ky H, Satharasinghe DA, Liew WC, Ong HK, Cheong SK, Kamarul T. Probable impact of age and hypoxia on proliferation and microRNA expression profile of bone marrow-derived human mesenchymal stem cells. PeerJ. 2016:e1536.

41. Mung KL, Tsui YP, Tai EW, Chan YS, Shum DK, Shea GK. Rapid and efficient generation of neural progenitors from adult bone marrow stromal cells by hypoxic preconditioning. Stem Cell Res Ther. 2016;7(1):146.

42. Dos Santos F, Andrade PZ, Boursa JS, Abecasis MM, da Silva CL, Cabral JM. Ex vivo expansion of human mesenchymal stem cells: a more effective cell proliferation kinetics and metabolism under hypoxia. J Cell Physiol. 2010;223(1):27–35.

43. Liu W, Rong Y, Wang J, Zhou Z, Ge X, Ji C, Jiang D, Gong F, Li L, Chen J, Zhao S, et al. Exosome-shuttled miR-216a-5p from hypoxic preconditioned mesenchymal stem cells repair traumatic spinal cord injury by shifting microglial M1/M2 polarization. J Neuroinflamm. 2020;17(1):47.

44. Lan Y-W, Choo K-B, Chen C-M, Hung T-H, Chen Y-B, Hsieh C-H, Kuo H-P, Chong K-Y. Hypoxia-preconditioned mesenchymal stem cells attenuate bleomycin-induced pulmonary fibrosis. Stem Cell Res Ther. 2015;6(1):97.

45. Wei N, Yu SP, Gu X, Taylor TM, Song D, Liu X, Wei L. Delayed intranasal delivery of hypoxic-preconditioned bone marrow mesenchymal stem cells enhanced cell homing and therapeutic benefits after ischemic stroke in mice. Cell Transplant. 2013;22(6):977–91.

46. Annabi B, Lee Y, Turcotte S, Naud E, Desrosiers RR, Champagne M, Eliopoulos N, Galipeau J, Béliveau R. Hypoxia promotes murine bone-marrow-derived stromal cell migration and tube formation. Stem Cells. 2003;21(3):337–47.

47. Wang X, Shen K, Wang J, Liu K, Wu G, Li Y, Luo L, Zheng Z, Hu D. Hypoxic preconditioning combined with curcumin promotes cell survival and mitochondrial quality of bone marrow mesenchymal stem cells, and accelerates cutaneous wound healing via PGC-1α/SIRT3/HIF-1α signaling. Free Radic Biol Med. 2020;159:164–76.

48. Wang Z, Fang B, Tan Z, Zhang D, Ma H. Hypoxic preconditioning increases the protective effect of bone marrow mesenchymal stem cells on spinal cord ischemia/reperfusion injury. Mol Med Rep. 2016;13(3):1953–60.
49. Peck SH, Bendigo JR, Tobias JW, Dodge GR, Malhotra NR, Mauck RL, Smith LJ. Hypoxic preconditioning enhances bone marrow-derived mesenchymal stem cell survival in a low oxygen and nutrient-limited 3D microenvironment. Cartilage. 2021;12(4):512–25.

50. Zhang HC, Liu XB, Huang S, Bi XY, Wang HX, Xie LX, et al. Microvesicles derived from human umbilical cord mesenchymal stem cells stimulated by hypoxia promote angiogenesis both in vitro and in vivo. Stem Cells Dev. 2012;21(18):3289–97.

51. Lavrentieva A, Majore I, Kasper C, Hass R. Effects of hypoxic culture conditions on umbilical cord-derived human mesenchymal stem cells. Cell Commun Signal. 2010;8:18.

52. Luo Z, Wu F, Xue E, Huang L, Yan P, Pan X, Zhou Y. Hypoxia preconditioning promotes bone marrow mesenchymal stem cells survival by inducing HIF-1α in injured neuronal cells derived exosomes culture system. Cell Death Dis. 2019;10(2):134.

53. Clarke L, van der Kooy D. Low oxygen enhances primitive and definitive neural stem cell colony formation by inhibiting distinct cell death pathways. Stem Cells. 2009;27(8):1879–86.

54. Mohyeldin A, Garzon-Muvdi T, Quinones-Hinojosa A. Oxygen in stem cell biology: a critical component of the stem cell niche. Cell Stem Cell. 2010;7(2):150–61.

55. Tomé M, Lindsay SL, Riddell JS, Barnett SC. Identification of nonepithelial multipotent cells in the embryonic olfactory mucosa. Stem Cells. 2009;27(9):2196–208.

56. Delorme B, Nivet E, Gaillard J, Häupl T, Ringe J, Devèze A, et al. The human nose harbors a niche of olfactory ecto-mesenchymal stem cells displaying neurogenic and osteogenic properties. Stem Cells Dev. 2010;19(6):853–66.

57. Lindsay SL, Johnstone SA, McGrath MA, Mallinson D, Barnett SC. Comparative miRNA-based fingerprinting reveals biological differences in human olfactory mucosa and bone-marrow-derived mesenchymal stromal cells. Stem Cell Res. 2016;6(5):729–42.

58. Lindsay SL, Johnstone SA, Mountford JC, Sheikh S, Allan DB, Clark L, Barnett SC. Human mesenchymal stem cells isolated from olfactory biopsies but not bone enhance CNS myelination in vitro. Glia. 2013;61(3):368–82.

59. Lindsay SL, Riddell JS, Barnett SC. Olfactory mucosa for transplant-mediated repair: a complex tissue for a complex injury? Glia. 2010;58(2):125–34.

60. Zhuo Y, Yuan T, Duan D, Wang L, Ge L, Wu P, Wang H, Lu M. Hypoxic condition promotes olfactory mucosa mesenchymal stem cells to differentiate into neurons and underlying mechanisms. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2016;41(12):1252–59.

61. Pellitteri R, Catania MV, Bonaccorso CM, Ranno E, Dell’Albani P, Zaecheo D. Viability of olfactory ensheathing cells after hypoxia and serum deprivation: implication for therapeutic transplantation. J Neurosci Res. 2014;92(12):1757–66.

62. Barraud P, He X, Zhao C, Ibanez C, Raha-Chowdhury R, Caldwell MA, Franklin RJ. Contrast imaging effects of basic fibroblast growth factor and epidermal growth factor on mouse neonatal olfactory mucosa cells. Eur J Neurosci. 2007;26(12):3345–57.

63. Zhang Y, Wang WT, Gong CR, Li C, Shi M. Combination of olfactory ensheathing cells and human umbilical cord mesenchymal stem cell-derived exosomes promotes sciatic nerve regeneration. Neural Regen Res. 2020;15(10):1903–11.

64. Barros CS, Franco SJ, Muller U. Extracellular matrix: functions in the nervous system. Cold Spring Harb Perspect Biol. 2011;3(1):a005108.

65. Fitch MT, Silver J. CNS injury, glial scars, and inflammation: inhibitory extracellular matrices and regeneration failure. Exp Neurol. 2008;209(2):294–301.

66. Brosis Lutz A, Barres BA. Contrasting the glial response to axon injury in the central and peripheral nervous systems. Dev Cell. 2014;28(1):7–17.

67. Fregnan F, Muratori L, Simoes AR, Giacobini-Robecchi MG, Raimondo S. Role of inflammatory cytokines in peripheral nerve injury. Neural Regen Res. 2012;7(29):2259–66.

68. Boruch AV, Conners JJ, Pipitone M, Deadwyler G, Storer PD, Devries GH, Jones KJ. Neurotrophic and migratory properties of an olfactory ensheathing cell line. Glia. 2001;33(3):225–29.

69. Lipson AC, Widenfalk J, Lindqvist E, Ebendal T, Olson L. Neurotrophic properties of olfactory ensheathing glia. Exp Neurol. 2003;180(2):167–71.

70. Woodhall E, West AK, Chuah MI. Cultured olfactory ensheathing cells express nerve growth factor, brain-derived neurotrophic factor, glia cell line-derived neurotrophic factor and their receptors. Brain Res Mol Brain Res. 2001;88(1–2):203–13.

71. Rosner J, Avalos P, Acosta F, Liu J, Drazin D. The potential for cellular therapy combined with growth factors in spinal cord injury. Stem Cells Int. 2012;2012:826754.

72. Wright AA, Todorovic M, Tello-Velasquez J, Rayfield AJ, St John JA, Ekberg JA. Enhancing the therapeutic potential of olfactory ensheathing cells in spinal cord repair using neurotrophins. Cell Transplant. 2018;27(6):867–78.

73. Houle JD, Ye JH. Survival of chronically-injured neurons can be prolonged by treatment with neurotrophic factors. Neuroscience. 1999;94(3):929–36.

74. Kwon BK, Liu J, Messerer C, Kobayashi NR, McGraw J, Oshicpok L, Tetzlaff W. Survival and regeneration of rubrospinal neurons 1 year after spinal cord injury. Proc Natl Acad Sci U S A. 2002;99(5):3246–51.

75. Schnell L, Schneider R, Kolbeck R, Barde YA, Schwab ME. Neurotrophin-3 enhances sprouting of corticospinal tract during development and after adult spinal cord lesion. Nature. 1994;367(6459):170–73.

76. Ma YH, Zhang Y, Cao L, Su JC, Wang ZW, Xu AB, Zhang SC. Effect of neurotrophin-3 genetically modified olfactory ensheathing cells transplantation on spinal cord injury. Cell Transplant. 2010;19(2):167–77.

77. Ye J, Xue R, Ji ZY, Zou CJ, Chen YQ, Wang JJ, Cheng XD. Effect of NT-3 on repair of spinal cord injury through the MAPK signaling pathway. Eur Rev Med Pharmacol Sci. 2020;24(5):2165–72.

78. Friedman WJ, Greene LA. Neurotrophin signaling via Trks and p75. Exp Cell Res. 1999;253(1):131–42.

79. Windus LC, Lineburg KE, Scott SE, Claxton C, Mackay-Sim A, Key B, St John JA. Lamellipodia mediate the
heterogeneity of central olfactory ensheathing cell interactions. Cell Mol Life Sci. 2010;67(10):1735–50.
80. Ciani L, Salinas PC. WNTs in the vertebrate nervous system: from patterning to neuronal connectivity. Nat Rev Neurosci. 2005;6(5):351–62.
81. Booker-Dwyer T, Hirsh S, Zhao H. A unique cell population in the mouse olfactory bulb displays nuclear beta-catenin signaling during development and olfactory sensory neuron regeneration. Dev Neurobiol. 2008;68(7):859–69.
82. Wang YZ, Molotkov A, Song L, Li Y, Pleasure DE, Zhou CJ. Activation of the Wnt/beta-catenin signaling reporter in developing mouse olfactory nerve layer marks a specialized subgroup of olfactory ensheathing cells. Dev Dyn. 2008;237(11):3157–68.
83. Zaghetto AA, Paina S, Mantero S, Platonova N, Peretto P, Bovetti S, Puche A, Piccolo S, Merlo GR. Activation of the Wnt-beta catenin pathway in a cell population on the surface of the forebrain is essential for the establishment of olfactory axon connections. J Neurosci. 2007;27(36):9757–68.
84. Wang YZ, Yamagami T, Gan Q, Wang Y, Zhao T, Hamad S, Lott P, Schnitke N, Schwob JE, Zhou CJ. Canonical Wnt signaling promotes the proliferation and neurogenesis of peripheral olfactory stem cells during postnatal development and adult regeneration. J Cell Sci. 2011;124(Pt 9):1553–63.
85. Fletcher RB, Das D, Gadye L, Street KN, Baudhuin A, Wagner A, Cole MB, Flores Q, Choi YG, Yosef N, Purdom E, et al. Deconstructing olfactory stem cell trajectories at single-cell resolution. Cell Stem Cell. 2017;20(6):817–30.e8.
86. Yue Y, Xue Q, Yang J, Li X, Mi Z, Zhao G, Zhang L. Wnt-activated olfactory ensheathing cells stimulate neural stem cell proliferation and neuronal differentiation. Brain Res. 2020;1735:146726.
87. Makridakis M, Roubelakis MG, Vlahou A. Stem cells: mucosa mesenchymal stem cell, a multiple potential stem cell. Stem Cells Int. 2016;2016:1243659.
88. Jafari M, Asghari A, Delbandi AA, Jalessi M, Jazayeri MH, Makridakis M, Roubelakis MG, Vlahou A. Stem cells: Wnt- regulated cofilin activation and 
89. Fletcher RB, Das D, Gadye L, Street KN, Baudhuin A, Wagner A, Cole MB, Flores Q, Choi YG, Yosef N, Purdom E, et al. Deconstructing olfactory stem cell trajectories at single-cell resolution. Cell Stem Cell. 2017;20(6):817–30.e8.
90. Ke C. Slit-2 repels the migration of olfactory ensheathing cells by triggering Ca2+ release and motility of olfactory ensheathing cells. Glia. 2006;54(6):536–44.
91. Su Z, Yuan Y, Chen J, Cao L, Zhu Y, Gao L, Qiu Y, He C. Reactive astrocytes in glial scar attract olfactory ensheathing cells migration by secreted TNF-alpha in spinal cord lesion of rat. PLoS ONE. 2009;4(12):e8141.
92. Li Y, Field PM, Raisman G. Regeneration of adult rat corticospinal axons induced by transplanted olfactory ensheathing cells. J Neurosci. 1998;18(24):10514–24.
93. Richter MW, Fletcher PA, Liu J, Tetzlaff W, Roskams AJ. Lamina propria and olfactory bulb ensheathing cells exhibit differential integration and migration and promote differential axon sprouting in the lesioned spinal cord. J Neurosci. 2005;25(46):10700–11.
94. Su Z, Yuan H, Rivkees SA. Lysophosphatidic acid regulates olfactory ensheathing cell migration with activation of ERK in spinal cord lesion of rat. J Neurosci. 2005;25(46):10700–11.
95. Nan B, Getchell ML, Partin JV, Getchell TV. Leukemia inhibitory factor, interleukin-6, and their receptors are expressed transiently in the olfactory mucosa after target ablation. J Comp Neurol. 2001;435(1):60–77.
96. Huang ZH, Wang Y, Su ZD, Geng JG, Chen YZ, Yuan XB, He C. Glial cell line-derived neurotrophic factor promotes olfactory ensheathing cells migration. Glia. 2006;54(6):536–44.
97. Windsor LC, Claxton C, Allen CL, Key B, St John JA. Motile membrane protrusions regulate cell-cell adhesion and migration of olfactory ensheathing glia. Glia. 2007;55(16):1708–19.
98. Ingram NT, Khankan RR, Phelps PE. Olfactory ensheathing cells express alpha7 integrin to mediate their migration on laminin. PLoS ONE. 2016;11(4):e0153394.
99. Hale DM, Ray S, Leung JY, Holloway AF, Chung RS, West AK, Chuah MI. Olfactory ensheathing cells moderate nuclear factor kappaB translocation in astrocytes. Mol Cell Neurosci. 2011;46(1):211–21.
100. Su Z, Yuan H, Liu D, Rikvées SA. Lysoosphatidic acid regulates the proliferation and migration of olfactory ensheathing cells in vitro. Glia. 2003;44(1):26–36.
101. Zhong W, Bian K, Hu Y, Ji Z, Xu X, Li J, Wu P, Wang X, Zhang Y, Zhang P, Zhang H, et al. Lysoosphatidic acid inhibits the homing of transplanted olfactory ensheathing cells to the lesion site after spinal cord injury in rats. Exp Cell Res. 2003;289(1):85–95.
102. Tseng YT, Chen M, Lai R, Oieni F, Smyth G, Anoopkumar-Dukie S, St John J. Erk/JNK modulation of olfactory ensheathing cell migration with activation of ERK and alteration of the extracellular matrix. Biomed Pharmacother. 2021;141:111819.
136. Entezari M, Mozafari M, Bakhtiyari M, Moradi F, Bagher Z, Soleimani M. Three-dimensional-printed polycaprolactone/polypyrrole conducting scaffolds for differentiation of human olfactory ecto-mesenchymal stem cells into Schwann cell-like phenotypes and promotion of neurite outgrowth. J Biomed Mater Res A. 2022;110(5):1134–46.

137. Silva NA, Sousa RA, Pires AO, Sousa N, Salgado AJ, Reis RL. Interactions between Schwann and olfactory ensheathing cells with a starch/polycaprolactone scaffold aimed at spinal cord injury repair. J Biomed Mater Res A. 2012;100(2):470–76.

138. Schnell E, Klinkhammer K, Balzer S, Brook G, Klee D, Dalton P, Mey J. Guidance of glial cell migration and axonal growth on electrospun nanofibers of poly-ε-caprolactone and a collagen/poly-ε-caprolactone blend. Biomaterials. 2007;28(19):3012–25.

139. Grzesiak J, Fryczkowski R, Lis A, Szarek D, Laska J, Marycz K. Characterization of olfactory ensheathing glial cells cultured on polyurethane/polylactide electrospun non-wovens. Int J Polym Sci. 2015;2015:908328.

140. Chan RTH, Russell RA, Marçal H, Lee TH, Holden PJ, Foster LJR. BioPEGylation of polyhydroxybutyrate promotes nerve cell health and migration. Biomacromolecules. 2014;15(1):339–49.

141. Zhang LL, Huang LH, Zhang ZX, Hao DJ, He BR. Compatibility of olfactory ensheathing cells with functionalized self-assembling peptide scaffold in vitro. Chin Med J (Engl). 2013;126(20):3891–96.

142. Ferrero-Gutierrez A, Menendez-Menendez Y, Alvarez-Viejo M, Meana A, Otero J. New serum-derived albumin scaffold seeded with adipose-derived stem cells and olfactory ensheathing cells used to treat spinal cord injured rats. Histol Histopathol. 2013;28(1):89–100.

143. Li J, Féron F, Mackay-Sim A, Waite PM. Olfactory ensheathing cells promote locomotor recovery after delayed transplantation into transected spinal cord. Brain. 2002;125(Pt 1):14–21.

144. Vishwakarma SK, Bardia A, Lakkireddy C, Paspala SAB, Khan AA. Bioengineering human neurological constructs using decellularized meningeal scaffolds for application in spinal cord injury. Front Bioeng Biotechnol. 2018;6:150.

145. Gupta SK, Mishra NC, Dhasmana A. Decellularization methods for scaffold fabrication. Methods Mol Biol. 2018;1577:1–10.

146. Chedly J, Soares S, Montembault A, von Boxberg Y, Veron-Ravaille M, Mouffle C, Benassy MN, Taxi J, David L, Nothias F. Physical chitosan microhydrogels as scaffolds for spinal cord injury restoration and axon regeneration. Biomaterials. 2017;138:91–107.

147. Bai YR, Lai BQ, Han WT, Sun JH, Li G, Ding Y, Zeng X, Ma YH, Zeng YS. Decellularized optic nerve functional scaffold transplant facilitates directional axon regeneration and remyelination in the injured white matter of the rat spinal cord. Neural Regen Res. 2021;16(11):2276–83.

148. Ma YH, Shi HJ, Wei QS, Deng QW, Sun JH, Liu Z, Lai BQ, Li G, Ding Y, Niu WT, Zeng YS, Zeng X. Developing a mechanically matched decellularized spinal cord scaffold for the in situ matrix-based neural repair of spinal cord injury. Biomaterials. 2021;279:12192.

149. Yu F, Li P, Du S, Lui KW, Lin Y, Chen L, Ren Q, Wang J, Mei J, Xiao J, Zhu J. Olfactory ensheathing cells seeded decellularized scaffold promotes axonal regeneration in spinal cord injury rats. J Biomed Mater Res A. 2021;109(5):779–87.

150. Vadi M, Spier P, Ralston A, Doherty D, Tello Velasquez J, Pastrana E, Diaz-Nido J, Lim F, Ekberg JA, Nguyen NT, St John JA. Generation of three-dimensional multiple spheroid model of olfactory ensheathing cells using floating liquid marbles. Sci Rep. 2015;5:15083.

151. Chen M, Shah MP, Shelper TB, Nazareth L, Barker M, Tello Velasquez J, Ekberg JAK, Vial ML, St John JA. Naked liquid marbles: a robust three-dimensional low-volume cell-culturing system. ACS Appl Mater Interfaces. 2019;11(10):9814–23.

152. Novikova LN, Lobov S, Wiberg M, Novikov LN. Efficacy of olfactory ensheathing cells to support regeneration after spinal cord injury is influenced by method of culture preparation. Exp Neurol. 2011;229(1):132–42.

153. Beckingham LJ, Todorovic M, Tello Velasquez J, Vial ML, Chen M, Ekberg JAK, St John JA. Three-dimensional cell culture can be regulated by vibration: low-frequency vibration increases the size of olfactory ensheathing cell spheroids. J Biol Eng. 2019;13:41.

154. Jouvial D, Truong V, Neitzke CC, Guo SZ, Walsh PJ, Monat JR, Meng F, Park SH, Dutton JR, Parr AM, McAlpine M. 3D printed stem-cell derived neural progenitors generate spinal cord scaffolds. Adv Funct Mater. 2018;28(39):1801850.

155. Liu X, Hao M, Chen Z, Zhang T, Huang J, Dai J, Zhang Z. 3D bioprinted neural tissue constructs for spinal cord injury repair. Biomaterials. 2021;272:120771.

156. Othon CM, Wu X, Anders JJ, Ringelstein BR. Single-cell printing to form three-dimensional lines of olfactory ensheathing cells. Biomed Mater. 2008;3(3):034101.